SI3419978T1 - Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK) - Google Patents

Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK)

Info

Publication number: SI3419978T1
Authority: SI; Slovenia
Prior art keywords: jak; pyrazin; pyrazolo; inhibitors; derivatives
Prior art date: 2016-02-24

Application number

SI201730289T

Other languages

English (en)

Inventor

Matthew Frank Brown

Alpay DERMENCI

Andrew Fensome

Brian Stephen Gerstenberger

Matthew Merrill Hayward

Dafydd Rhys Owen

Stephen Wayne Wright

Li Huang Xing

Xiaojing Yang

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-24

Filing date

2017-02-10

Publication date

2020-08-31

2017-02-10 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2020-08-31 Publication of SI3419978T1 publication Critical patent/SI3419978T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

SI201730289T 2016-02-24 2017-02-10 Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK) SI3419978T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662299130P	2016-02-24	2016-02-24
PCT/IB2017/050748 WO2017144995A1 (en)	2016-02-24	2017-02-10	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EP17705705.6A EP3419978B1 (en)	2016-02-24	2017-02-10	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors

Publications (1)

Publication Number	Publication Date
SI3419978T1 true SI3419978T1 (sl)	2020-08-31

Family

ID=58054385

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201730289T SI3419978T1 (sl)	2016-02-24	2017-02-10	Derivati pirazolo(1,5-A)pirazin-4-ila kot zaviralci z janusom povezane kinaze (JAK)

Country Status (45)

Country	Link
US (4)	US10144738B2 (sl)
EP (2)	EP3712153B1 (sl)
JP (1)	JP6505956B2 (sl)
KR (1)	KR102128671B1 (sl)
CN (1)	CN109071546B (sl)
AR (1)	AR107714A1 (sl)
AU (1)	AU2017222417B2 (sl)
CA (1)	CA2958490C (sl)
CL (1)	CL2018002358A1 (sl)
CO (1)	CO2018008799A2 (sl)
CR (1)	CR20180372A (sl)
CU (1)	CU24511B1 (sl)
CY (1)	CY1122949T1 (sl)
DK (1)	DK3419978T3 (sl)
DO (1)	DOP2018000187A (sl)
EA (1)	EA035036B1 (sl)
EC (1)	ECSP18072109A (sl)
ES (1)	ES2794779T3 (sl)
GE (1)	GEP20217242B (sl)
HK (1)	HK1258157A1 (sl)
HR (1)	HRP20200781T1 (sl)
HU (1)	HUE049305T2 (sl)
IL (1)	IL260923B (sl)
LT (1)	LT3419978T (sl)
MA (2)	MA52987A (sl)
MD (1)	MD3419978T2 (sl)
ME (1)	ME03743B (sl)
MX (1)	MX2018010236A (sl)
MY (1)	MY189118A (sl)
NI (1)	NI201800080A (sl)
NZ (1)	NZ744349A (sl)
PH (1)	PH12018501788A1 (sl)
PL (1)	PL3419978T3 (sl)
PT (1)	PT3419978T (sl)
RS (1)	RS60261B1 (sl)
RU (1)	RU2718902C2 (sl)
SG (1)	SG11201806307YA (sl)
SI (1)	SI3419978T1 (sl)
SV (1)	SV2018005726A (sl)
TN (1)	TN2018000295A1 (sl)
TW (1)	TWI665201B (sl)
UA (1)	UA119835C2 (sl)
UY (1)	UY37133A (sl)
WO (1)	WO2017144995A1 (sl)
ZA (1)	ZA201804972B (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3419978T3 (da)	2016-02-24	2020-06-02	Pfizer	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
AU2019227607C1 (en)	2018-02-27	2023-07-20	Incyte Corporation	Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CA3090842A1 (en)	2018-03-12	2019-09-19	Abbvie Inc.	Inhibitors of tyrosine kinase 2 mediated signaling
MX2020012201A (es)	2018-05-17	2021-01-29	Bayer Ag	Derivados sustituidos de la carboxamida dihidropirazolo pirazina.
JP7391046B2 (ja)	2018-05-18	2023-12-04	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
SG11202013216RA (en)	2018-07-05	2021-01-28	Incyte Corp	Fused pyrazine derivatives as a2a / a2b inhibitors
AR116592A1 (es)	2018-10-17	2021-05-26	Lilly Co Eli	Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220204513A1 (en) *	2019-04-12	2022-06-30	Primegene (Beijing) Co., Ltd.	Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
IL287665A (en)	2019-04-30	2022-07-01	Celgene Corp	Combination therapies comprising apremilast and tyk2 inhibitors
MX2022002995A (es) *	2019-09-11	2022-06-02	Pfizer	Tratamiento de hidradenitis con inhibidores de quinasa.
WO2021124095A1 (en) *	2019-12-18	2021-06-24	Pfizer Inc.	Treatment of ulcerative colitis with kinase inhibitors
US20230149407A1 (en)	2020-04-04	2023-05-18	Pfizer Inc.	Methods of Treating Coronavirus Disease 2019
EP4132931A1 (en) *	2020-04-08	2023-02-15	Pfizer Inc.	Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
JP2023542298A (ja) *	2020-09-11	2023-10-06	プルモシムセラピューティクスリミテッドライアビリティカンパニー	肺高血圧症を治療又は予防する組成物及び方法
CN112592345B (zh) *	2020-12-07	2024-09-13	嘉兴特科罗生物科技有限公司	一种三氮唑并吡嗪类化合物及其用途
WO2022165530A1 (en) *	2021-02-01	2022-08-04	Janssen Biotech, Inc.	Small molecule inhibitors of salt inducible kinases
CA3215278A1 (en)	2021-03-30	2022-10-06	Pfizer Inc.	Methods for treatment of vitiligo
KR20240111312A (ko)	2021-10-25	2024-07-16	카이메라 쎄라퓨틱스 인코포레이티드	Tyk2 분해제 및 이의 용도
US20250011332A1 (en) *	2021-11-12	2025-01-09	Soter Biopharma Pte. Ltd.	Pyrazolo fused ring compound and use thereof
WO2024235167A1 (zh) *	2023-05-12	2024-11-21	海南康哲美丽科技有限公司	一种吡唑并吡嗪类化合物及其晶型的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101679408B (zh)	2006-12-22	2016-04-27	Astex治疗学有限公司	作为fgfr抑制剂的双环杂环化合物
AR066879A1 (es) *	2007-06-08	2009-09-16	Novartis Ag	Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP3031324A3 (en)	2008-06-10	2016-09-07	AbbVie Inc.	Tricyclic kinase inhibitors
WO2010016005A1 (en)	2008-08-06	2010-02-11	Pfizer Inc.	6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
WO2010117787A2 (en)	2009-03-30	2010-10-14	The Brigham And Women's Hospital, Inc.	Inhibiting eph b-3 kinase
UY33213A (es) *	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
MX2012011941A (es) *	2010-04-14	2013-08-27	Array Biopharma Inc	Imidazo [1, 2-c] pirimidinas 5, 7-substituidas como inhibidores de jak cinasas.
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
WO2013055645A1 (en)	2011-10-12	2013-04-18	Array Biopharma Inc.	5,7-substituted-imidazo[1,2-c]pyrimidines
EP2832734A4 (en) *	2012-03-28	2015-08-26	Takeda Pharmaceutical	HETEROCYCLIC COMPOUND
HUE030067T2 (en)	2012-03-28	2017-04-28	Merck Patent Gmbh	Bicyclic pyrazinone derivatives
US9376441B2 (en)	2013-07-31	2016-06-28	Gilead Sciences, Inc.	Substituted pyrrolidines as SYK inhibitors
TW201605811A (zh)	2013-12-11	2016-02-16	阿爾米雷爾有限公司	作為jak抑制劑之吡唑并嘧啶-2基衍生物
US9856263B2 (en) *	2014-04-28	2018-01-02	Pfizer Inc.	Heteroaromatic compounds and their use as dopamine D1 ligands
WO2016009028A1 (fr)	2014-07-17	2016-01-21	Valeo Systèmes d'Essuyage	Balai plat caréné d'essuie-glace
CN107278203B (zh) *	2014-12-05	2020-05-19	阵列生物制药公司	作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪
TW201639845A (zh)	2015-01-29	2016-11-16	和記黃埔醫藥（上海）有限公司	新的雜芳基和雜環化合物、其組成物及方法
CA2976109A1 (en)	2015-02-13	2016-08-18	Dana-Farber Cancer Institute, Inc.	Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors
GB201504565D0 (en)	2015-03-18	2015-05-06	Takeda Pharmaceutical	Novel compounds
HUE044240T2 (hu)	2015-04-29	2019-10-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus kináz (JAK) inhibitorok
EP3394066A2 (en)	2015-12-22	2018-10-31	H. Hoffnabb-La Roche Ag	PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
DK3419978T3 (da)	2016-02-24	2020-06-02	Pfizer	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
US10703757B2 (en)	2016-12-23	2020-07-07	Plexxikon Inc.	Compounds and methods for CDK8 modulation and indications therefor
CN110267960B (zh)	2017-01-18	2022-04-26	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018234342A1 (en)	2017-06-21	2018-12-27	F. Hoffmann-La Roche Ag	ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4
US11254668B2 (en)	2017-08-14	2022-02-22	Pfizer Inc.	Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives

2017
- 2017-02-10 DK DK17705705.6T patent/DK3419978T3/da active
- 2017-02-10 JP JP2018544300A patent/JP6505956B2/ja active Active
- 2017-02-10 UA UAA201808148A patent/UA119835C2/uk unknown
- 2017-02-10 MD MDE20190031T patent/MD3419978T2/ro unknown
- 2017-02-10 GE GEAP201714864A patent/GEP20217242B/en unknown
- 2017-02-10 ME MEP-2020-97A patent/ME03743B/me unknown
- 2017-02-10 TN TNP/2018/000295A patent/TN2018000295A1/en unknown
- 2017-02-10 KR KR1020187024431A patent/KR102128671B1/ko active IP Right Grant
- 2017-02-10 MA MA052987A patent/MA52987A/fr unknown
- 2017-02-10 AU AU2017222417A patent/AU2017222417B2/en active Active
- 2017-02-10 MA MA43668A patent/MA43668B1/fr unknown
- 2017-02-10 SG SG11201806307YA patent/SG11201806307YA/en unknown
- 2017-02-10 RU RU2018130547A patent/RU2718902C2/ru active
- 2017-02-10 CO CONC2018/0008799A patent/CO2018008799A2/es unknown
- 2017-02-10 MY MYPI2018702937A patent/MY189118A/en unknown
- 2017-02-10 PL PL17705705T patent/PL3419978T3/pl unknown
- 2017-02-10 WO PCT/IB2017/050748 patent/WO2017144995A1/en active Application Filing
- 2017-02-10 MX MX2018010236A patent/MX2018010236A/es unknown
- 2017-02-10 CU CU2018000078A patent/CU24511B1/es unknown
- 2017-02-10 PT PT177057056T patent/PT3419978T/pt unknown
- 2017-02-10 HU HUE17705705A patent/HUE049305T2/hu unknown
- 2017-02-10 EA EA201891463A patent/EA035036B1/ru unknown
- 2017-02-10 SI SI201730289T patent/SI3419978T1/sl unknown
- 2017-02-10 NZ NZ744349A patent/NZ744349A/en unknown
- 2017-02-10 CR CR20180372A patent/CR20180372A/es unknown
- 2017-02-10 CN CN201780013165.4A patent/CN109071546B/zh active Active
- 2017-02-10 EP EP20168877.7A patent/EP3712153B1/en active Active
- 2017-02-10 RS RS20200584A patent/RS60261B1/sr unknown
- 2017-02-10 EP EP17705705.6A patent/EP3419978B1/en active Active
- 2017-02-10 ES ES17705705T patent/ES2794779T3/es active Active
- 2017-02-10 LT LTEP17705705.6T patent/LT3419978T/lt unknown
- 2017-02-21 TW TW106105777A patent/TWI665201B/zh active
- 2017-02-21 CA CA2958490A patent/CA2958490C/en active Active
- 2017-02-21 US US15/437,618 patent/US10144738B2/en active Active
- 2017-02-22 UY UY0001037133A patent/UY37133A/es unknown
- 2017-02-23 AR ARP170100462A patent/AR107714A1/es active IP Right Grant
2018
- 2018-07-18 SV SV2018005726A patent/SV2018005726A/es unknown
- 2018-07-24 ZA ZA2018/04972A patent/ZA201804972B/en unknown
- 2018-08-01 IL IL260923A patent/IL260923B/en unknown
- 2018-08-03 NI NI201800080A patent/NI201800080A/es unknown
- 2018-08-17 CL CL2018002358A patent/CL2018002358A1/es unknown
- 2018-08-23 PH PH12018501788A patent/PH12018501788A1/en unknown
- 2018-08-24 DO DO2018000187A patent/DOP2018000187A/es unknown
- 2018-09-24 EC ECSENADI201872109A patent/ECSP18072109A/es unknown
- 2018-11-06 US US16/181,596 patent/US10822341B2/en active Active
2019
- 2019-01-14 HK HK19100512.8A patent/HK1258157A1/zh unknown
2020
- 2020-05-13 HR HRP20200781TT patent/HRP20200781T1/hr unknown
- 2020-05-15 CY CY20201100470T patent/CY1122949T1/el unknown
- 2020-09-08 US US17/014,533 patent/US11472809B2/en active Active
2022
- 2022-09-07 US US17/939,375 patent/US12129256B2/en active Active

Also Published As

Publication number	Publication date
KR102128671B1 (ko)	2020-06-30
HK1258157A1 (zh)	2019-11-08
LT3419978T (lt)	2020-06-10
KR20180103158A (ko)	2018-09-18
TW201741313A (zh)	2017-12-01
IL260923B (en)	2022-01-01
ECSP18072109A (es)	2018-10-31
CR20180372A (es)	2018-09-19
MA52987A (fr)	2021-04-28
CA2958490C (en)	2024-02-27
BR112018015501A2 (pt)	2018-12-18
RU2018130547A3 (sl)	2020-03-25
WO2017144995A1 (en)	2017-08-31
CN109071546B (zh)	2021-03-02
EP3419978A1 (en)	2019-01-02
DOP2018000187A (es)	2019-01-31
CN109071546A (zh)	2018-12-21
US10822341B2 (en)	2020-11-03
US10144738B2 (en)	2018-12-04
US20230045252A1 (en)	2023-02-09
SV2018005726A (es)	2018-10-24
MA43668B1 (fr)	2020-05-29
UY37133A (es)	2017-09-29
CA2958490A1 (en)	2017-08-24
RS60261B1 (sr)	2020-06-30
PH12018501788A1 (en)	2019-06-17
AU2017222417A1 (en)	2018-08-02
CU20180078A7 (es)	2019-02-04
JP6505956B2 (ja)	2019-04-24
ES2794779T3 (es)	2020-11-19
US20170240552A1 (en)	2017-08-24
CO2018008799A2 (es)	2018-09-20
US11472809B2 (en)	2022-10-18
JP2019510003A (ja)	2019-04-11
AU2017222417B2 (en)	2020-07-09
MY189118A (en)	2022-01-26
TWI665201B (zh)	2019-07-11
NI201800080A (es)	2018-11-22
RU2718902C2 (ru)	2020-04-15
PL3419978T3 (pl)	2020-11-30
CU24511B1 (es)	2021-05-12
PT3419978T (pt)	2020-06-01
MD3419978T2 (ro)	2020-07-31
CL2018002358A1 (es)	2018-11-30
CY1122949T1 (el)	2021-10-29
HUE049305T2 (hu)	2020-09-28
RU2018130547A (ru)	2020-03-25
ME03743B (me)	2021-04-20
UA119835C2 (uk)	2019-08-12
SG11201806307YA (en)	2018-09-27
EA201891463A1 (ru)	2019-03-29
US20190071448A1 (en)	2019-03-07
US20200399281A1 (en)	2020-12-24
US12129256B2 (en)	2024-10-29
MX2018010236A (es)	2019-01-14
EP3712153A1 (en)	2020-09-23
EP3419978B1 (en)	2020-04-15
ZA201804972B (en)	2019-06-26
HRP20200781T1 (hr)	2020-07-24
GEP20217242B (en)	2021-04-12
AR107714A1 (es)	2018-05-23
NZ744349A (en)	2023-06-30
TN2018000295A1 (en)	2020-01-16
DK3419978T3 (da)	2020-06-02
EP3712153B1 (en)	2021-12-01
EA035036B1 (ru)	2020-04-20

Publication	Publication Date	Title
HK1258157A1 (zh)	2019-11-08	作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
HRP20211261T8 (hr)	2022-01-21	[1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola
SI3583105T1 (sl)	2024-06-28	Derivati pirolo (1,2-B)piridazina
HK1256751A1 (zh)	2019-10-04	[1，2，4]三唑並[1，5-a]嘧啶-7-基化合物
IL266305B (en)	2021-10-31	History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
IL254224A0 (en)	2017-10-31	7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1254809A1 (zh)	2019-07-26	治療中有用的吡唑並[1，5-a]三嗪-4-胺衍生物
ZA201605666B (en)	2021-01-27	Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en)	2022-10-01	Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL262673A (en)	2018-12-31	A pyrazolo[5,1-a]pyrimidine compound
IL280211A (en)	2021-03-01	History of triazoloquinoxaline with additional transformations
IL272988A (en)	2020-04-30	Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
SI3362453T1 (sl)	2022-06-30	Derivati cikličnega etra pirazolo(1,5-A)pirimidin-3-karboksiamida